Cosette M Wheeler Selected Research

Adenocarcinoma in Situ

1/2012	Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
12/2011	Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
3/2011	Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
4/2009	The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
5/2007	Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cosette M Wheeler Research Topics

Disease

28	Infections 01/2022 - 10/2002
28	Uterine Cervical Dysplasia 01/2021 - 11/2002
24	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 01/2003
20	Neoplasms (Cancer) 01/2022 - 01/2003
18	Papillomavirus Infections 01/2021 - 07/2004
9	Atypical Squamous Cells of the Cervix 12/2016 - 03/2002
8	Squamous Intraepithelial Lesions 12/2016 - 03/2002
7	Persistent Infection 10/2016 - 05/2005
5	Papilloma (Papillomatosis) 01/2020 - 01/2012
5	Adenocarcinoma in Situ 01/2012 - 05/2007
3	Genital Diseases 03/2010 - 05/2005
3	Condylomata Acuminata (Genital Wart) 03/2010 - 05/2005
2	Carcinoma (Carcinomatosis) 01/2022 - 06/2003
2	Reinfection 01/2020 - 10/2009
2	Warts (Wart) 01/2018 - 07/2010
2	Carcinogenesis 11/2015 - 06/2005
2	Coinfection 01/2012 - 02/2009
1	Prostatic Neoplasms (Prostate Cancer) 10/2017
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015
1	Vulvar Diseases 10/2009
1	Hepatitis B 01/2008
1	Injection Site Reaction 07/2004
1	Herpes Simplex 01/2003

Drug/Important Bio-Agent (IBA)

37	VaccinesIBA 01/2022 - 11/2002
22	DNA (Deoxyribonucleic Acid)IBA 11/2015 - 03/2002
12	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2018 - 04/2007
4	Virus-Like Particle VaccinesIBA 12/2011 - 06/2007
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2012
3	AntibodiesIBA 01/2020 - 10/2009
2	EpitopesIBA 01/2022 - 01/2020
2	EnzymesIBA 02/2015 - 06/2003
2	Combined VaccinesIBA 07/2010 - 05/2005
2	Oral ContraceptivesIBA 02/2010 - 12/2005
2	SolutionsIBA 08/2008 - 03/2002
2	HLA Antigens (Human Leukocyte Antigens)IBA 10/2005 - 08/2004
1	Formaldehyde (Formol)FDA Link 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	Immunodominant EpitopesIBA 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020
1	Long Noncoding RNAIBA 10/2017
1	P-2 (P 2)IBA 12/2016
1	Hormones (Hormone)IBA 10/2014
1	CarcinogensIBA 06/2014
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2014
1	Adenosine Triphosphate (ATP)IBA 01/2012
1	ParaffinIBA 04/2009
1	Proteins (Proteins, Gene)FDA Link 02/2008
1	Histocompatibility Antigens Class IIBA 02/2008
1	tapasinIBA 02/2008
1	Biological ProductsIBA 06/2007
1	Complement System Proteins (Complement)IBA 01/2007
1	Contraceptive Agents (Contraceptives)IBA 12/2005
1	NucleotidesIBA 07/2005
1	CI 22IBA 07/2005
1	Immunoglobulin G (IgG)IBA 06/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2005
1	A-Form DNA (A-DNA)IBA 01/2005
1	HLA-DRB1 Chains (HLA DRB1)IBA 08/2004
1	Indicators and Reagents (Reagents)IBA 10/2002

Therapy/Procedure

2	Microspheres (Microsphere) 02/2008 - 03/2005
1	Hormonal Contraception 01/2016
1	Condoms (Condom) 01/2016
1	Therapeutics 03/2010
1	Secondary Prevention 11/2009
1	Aftercare (After-Treatment) 05/2007
1	Injections 12/2005